FDA Approves Ibrutinib in Pediatric Patients With Chronic GVHD

Article

Based on results of the phase 1/2 iMAGINE trial, the FDA has approved ibrutinib for pediatric patients with chronic graft-versus-host disease.

The FDA has approved ibrutinib (Imbruvica) as an oral suspension or in the form of capsules and tablets for pediatric patients 1 year or older with chronic graft-versus-host-disease (GVHD) who have experience with 1 or more prior lines of failed therapy, according to a press release from the FDA.

Results from the approval were based on the phase 1/2 iMAGINE trial (NCT03790332) which enrolled patients ages 1 to less than 22 years old with moderate-to-severe GVHD (n = 47). The overall response rate through week 25 was 60% (95% CI, 44%-74%), and the median duration of response was 5.3 months (95% CI, 2.8-8.8). From first response through events of either death or new systemic therapies for chronic GVHD, the median time was 14.8 months (95% CI, 4.6-not evaluable).

Overall, patients were excluded if they had single organ genitourinary involvement as the only manifestation of chronic GVHD. The median patient age in the population was 13 years (range, 1-19), with 70% of patients being male.

For patients 12 years or older, the recommended dose of ibrutinib is 420 mg orally once daily, and 240 mg/m2 once daily for those under 12. Patients can continue treatment until progression, recurrence, or unacceptable toxicity.

Common adverse effects included anemia, musculoskeletal pain, pyrexia, pneumonia, abdominal pain, stomatitis, thrombocytopenia, and headache.

Reference

FDA approves ibrutinib for pediatric patients with chronic graft versus host disease, including new oral suspension. News Release. FDA. August 24, 2022. Accessed August 24, 2022. https://bit.ly/3cgRdJ8

Recent Videos
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Related Content
Improving Disease Modification and Immune Responses in Myelofibrosis With Pelabresib

Improving Disease Modification and Immune Responses in Myelofibrosis With Pelabresib

ONCOLOGY Staff
November 16th 2024
Article

David M. Swoboda, MD, and Andrew Kuykendall, MD, spoke about the current treatment strategies and potential advancements that may improve outcomes such as spleen volume reduction in the myelofibrosis field.

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Leveraging Ex Vivo Gene Therapy Advancements in Hemoglobinopathies and Metabolic Diseases

Alexis K. Kuhn, PharmD, BCOP ;Katie Bruce, PharmD, BCPPS;Susie Long, PharmD
October 21st 2024
Podcast

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Vascular biomarkers reveal a unique toxicity profile of posttransplant cyclophosphamide: secondary analysis of BMT CTN 0402 and 1202

Vascular biomarkers reveal a unique toxicity profile of posttransplant cyclophosphamide: secondary analysis of BMT CTN 0402 and 1202

American Society for Transplantation and Cellular Therapy
October 30th 2024
Article

Posttransplant cyclophosphamide leads to unique changes in vascular biomarkers, revealing a distinct toxicity profile compared to other GVHD prophylaxis regimens.

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

Managing Secondary Cancer Risks After CAR T-Cell Therapy in Multiple Myeloma Subgroups

Rahul Banerjee, MD, FACP;Noopur Raje, MD
September 2nd 2024
Podcast

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

Data from the IMerge trial affirm the enduring responses and clinical benefit with imetelstat in those with transfusion-dependent MDS.

Lower-Risk MDS Population Has Enduring RBC-TI Following Imetelstat Therapy

Ashling Wahner
September 8th 2024
Article

Data from the IMerge trial affirm the enduring responses and clinical benefit with imetelstat in those with transfusion-dependent MDS.

Data from the PERSEUS trial support the benefit of D-VRd and DR maintenance as a standard of care in transplant-eligible newly diagnosed multiple myeloma.

Subcutaneous Daratumumab Combo Improves MRD-Negative Status in NDMM

Chris Ryan
September 7th 2024
Article

Data from the PERSEUS trial support the benefit of D-VRd and DR maintenance as a standard of care in transplant-eligible newly diagnosed multiple myeloma.